131 filings
8-K
MRNS
Marinus Pharmaceuticals Inc
15 Apr 24
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
7:32am
8-K
MRNS
Marinus Pharmaceuticals Inc
27 Mar 24
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
4:05pm
8-K
MRNS
Marinus Pharmaceuticals Inc
5 Mar 24
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:05pm
8-K
MRNS
Marinus Pharmaceuticals Inc
4 Jan 24
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
7:04am
8-K
MRNS
Marinus Pharmaceuticals Inc
28 Nov 23
Other Events
7:05am
8-K
dk10wy6
7 Nov 23
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
7:11am
8-K
9thw85 us9
28 Sep 23
Other Events
7:05am
8-K
f8nagqzayyc2
19 Sep 23
Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event
8:02am
8-K
d35vevdcdbwwnx2kp33w
21 Aug 23
Other Events
7:00am
8-K
shplsnu9ocwsscka
15 Aug 23
Other Events
7:00am
8-K
4ieo xfm0
10 Aug 23
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
7:10am
8-K
uz6f6v
1 Aug 23
ZTALMY is the first treatment approved by the European Commission for seizures associated with CDKL5 deficiency disorder in children and adolescents
4:05pm
8-K
sdg7187j3
30 May 23
The European Commission decision is expected within 67 days of the CHMP opinion
4:05pm
8-K
eq236epcxngwf15
30 May 23
Submission of Matters to a Vote of Security Holders
8:45am
8-K
1ruw7j7yjdnm3drslpke
17 May 23
Departure of Directors or Certain Officers
4:02pm
8-K
0z8glt0659
11 May 23
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
7:03am
8-K
ckk25md qz9z3
18 Apr 23
Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors
7:05am
8-K
l7gp94 h5kfw7zlf1
31 Mar 23
Entry into a Material Definitive Agreement
5:12pm
8-K
jtrj5dcm 15j
22 Mar 23
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
6:09pm
8-K
aebjef2s9clg3
10 Mar 23
Other Events
4:23pm